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ABSTRACT 
A series of 1-(4-methylquinolin-2-yl)-4,6-diaryl-1H-pyrazolo[3,4-b]pyridin-3-amine derivatives was synthesized 
by the reaction of 3-cinnamoyl-4-hydroxy-6-methyl-2H-pyran-2-ones with 2-chloro-4,6-diphenylnicotinonitrile 
analogues in the presence of 2-hydrazino-4-methyl quinoline and ethanol. The newly synthesized compounds 
were characterized by IR, 1H NMR and mass spectral data. The synthetic series of novel quinoline-
pyrazolopyridine hybrids were screened for in vitro schizont maturation assay against chloroquine sensitive 3D7 
strain of Plasmodium falciparum, from which the most five active analogues were further evaluated for in vivo 
4-day suppressive test in Swiss albino mice. Among the series, 5p (containing 4-Cl substituent attached to both 
aryl ring) portrayed considerable potent antimalarial activity during in vitro as well as in vivo study.  
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INTRODUCTION 
Malaria is a mosquito-borne disease 
caused by Plasmodium parasites that infects 
and destroys red blood cells, leading to fe-
ver, severe anaemia, cerebral malaria and if 
untreated, it even results in death (Baragana 
et al., 2011). Malaria remains one of the crit-
ical global health problems, with 214 million 
cases causing 438,000 deaths in 2015, ac-
cording to WHO estimates. Particularly sus-
ceptible groups include pregnant women and 
young children (Boudhar et al., 2016). 
Chemotherapeutic cure of malaria is becom-
ing progressively more challenging with the 
fast development of resistance of Plasmodi-
um falciparum, the most vicious and lethal 
malaria parasite, to many of the standard 
amine antimalarial drugs like chloroquine 
and artesunate (Miura et al.,2010; Gupta et 
al., 2010; Dondrop et al., 2009). Therefore, 
an urgent need exists for the development of 
new simple, safe, and more effective antima-
larial drugs. 
Quinoline nucleus has been extensively 
employed as core scaffold in the evolution of 
anti-malarial agents. Substituted quinolones 
derivatives are considered as remarkable 
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tools for the eradication of malaria. In order 
to overcome the challenge of resistance, var-
ious heterocycles have also been explored to 
develop new anti-malarial regents, pyra-
zolopyridines being one of them (Kumar et 
al., 2014). Hybridization concept has been 
proved as a lead for developing new anti-
malarial active agents (Menezes et al., 2002; 
Silva et al., 2016). In the present study, we 
have developed hybrids of pyrazolopyridine 
based quinoline for anti-malarial potential.  
 
MATERIALS AND METHODS 
Chemistry 
The synthetic procedure is given in Fig-
ure 1. 
Synthesis of 2-oxo-4, 6-diphenyl-1,2-
dihydropyridine-3-carbonitrile derivatives (3 
a-t) 
Synthesis was carried out as per proce-
dure reported in literature (Jain et al., 1995). 
A mixture of aromatic aldehydes, ketones, 
ethyl cyanoacetate (0.01 mol) and ammoni-
um acetate (0.08 mol) in n-butanol (20 ml) 
was refluxed for 3 h. The obtained precipi-
tate was filtered and washed successively 
with ethanol. 
Synthesis of 2-chloro-4,6-
diphenylnicotinonitrile derivatives (4 a-t) 
A suspension of pyridone compound 1, 
phosphorus pentachloride and phosphorus 
oxychloride was heated on a water bath for 
3 h. The reaction mixture was poured gradu-
ally into ice-cold water and neutralized by 
dilute ammonia solution. The separated solid 
was filtered and recrystallized from ethanol 
to afford the corresponding chloro derivative 
(Hamdy and Gamal-Eldeen, 2009). 
Synthesis of 1-(4-methylquinolin-2-yl)-4,6-
diaryl-1H-pyrazolo[3,4-b]pyridin-3-amine 
derivatives (5 a-t) 
The target compounds were synthesized 
by reported procedure (Hamdy and Gamal-
Eldeen, 2013). Chloro derivatives 4(a-t) 
(10 mmol) in absolute ethanol (30 ml) was 
added with excess of 2-hydrazino-4-methyl 
quinoline (10 mmol) and the mixture was re-
fluxed for 12 h. The solution was cooled, fil-
tered and recrystallized from acetic acid af-
forded 5(a-t). 
 
Figure 1: Synthesis of quinoline-pyrazolopyridine analogues 5a-t. Reagents and Conditions: a) Ethyl 
cyanoacetate, Ammonium acetate, BuOH, reflux, 3 hr. b) POCl3, PCl5, ∆, 3 hr. c) EtOH, reflux, 12 hr 
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1-(4-methylquinolin-2-yl)-4,6-diphenyl-1H-
pyrazolo[3,4-b]pyridin-3-amine (5a) 
Yield- 66 %; M.pt.- 150 °C; IR- NH2 str 
(3451, 3343), =C-H Str (3050), C=N (1600); 
1HNMR (CDCl3) δ- 8.19 (s, 1H, 3rd position 
of quinoline), 7.1-7.8 (m, 15H, aromatic 
ring), 5.6 (s, 2H, NH2), 2.61 (s, 3H, CH3 of 
quinoline); m/e- 428.34 (M+1); Calculated- 
C=78.67, H=4.95, N=16.38; found C=78.59, 
H=4.32, N=16.42. 
6-(4-fluorophenyl)-1-(4-methylquinolin-2-
yl)-4-phenyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5b) 
Yield- 69 %; M.pt.- 156-158 °C; IR- 
NH2 str (3450, 3347), =C-H Str (3053), C=N 
(1602), C-F (600); 1HNMR (CDCl3) δ- 8.32 
(s, 1H, 3rd position of quinoline), 7.2-7.7 (m, 
14H, aromatic ring), 5.4 (s, 2H, NH2), 2.63 
(s, 3H, CH3 of quinoline); m/e- 446.23 
(M+1); Calculated- C=75.49, H=4.53, 
N=15.72; found C=75.23, H=4.46, N=15.65. 
6-(4-methoxyphenyl)-1-(4-methylquinolin-2-
yl)-4-phenyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5c) 
Yield- 72 %; M.pt.- 163-166 °C; IR- 
NH2 str (3455, 3346), =C-H Str (3048), C=N 
(1605), C-O-C (1152); 1HNMR (CDCl3) δ- 
8.24 (s, 1H, 3rd position of quinoline), 7.3-
7.9 (m, 14H, aromatic ring), 5.6 (s, 2H, 
NH2), 3.82 (s, 3H, OCH3), 2.65 (s, 3H, CH3 
of quinoline); m/e-458.23 (M+1); Calculat-
ed- C=76.13, H=5.07, N=15.31; found 
C=76.46, H=5.03, N=15.67. 
1-(4-methylquinolin-2-yl)-4-phenyl-6-
(thiophen-2-yl)-1H-pyrazolo[3,4-b]pyridin-
3-amine (5d) 
Yield- 65 %; M.pt.- 165-167 °C; IR- 
NH2 str (3460, 3350), =C-H Str (3056), C=N 
(1604); 1HNMR (CDCl3) δ- 8.23 (s, 1H, 3rd 
position of quinoline), 7.2-7.7 (m, 13H, aro-
matic ring), 5.4 (s, 2H, NH2), 2.66 (s, 3H, 
CH3 of quinoline); m/e- 434.45 (M+1); Cal-
culated- C=72.03. H=4.42, N=16.15; found 
C=72.12, H=4.56, N=16.23. 
1-(4-methylquinolin-2-yl)-6-phenyl-4-p-tolyl-
1H-pyrazolo[3,4-b]pyridin-3-amine (5e) 
Yield- 69 %; M.pt.- 158-160 °C; IR- 
NH2 str (3453, 3339), =C-H Str (3054), C=N 
(1603); 1HNMR (CDCl3) δ- 8.15 (s, 1H, 3rd 
position of quinoline), 7.3-7.9 (m, 14H, aro-
matic ring), 5.4 (s, 2H, NH2), 2.59 (s, 3H, 
CH3 of quinoline), 2.23 (s, 3H, CH3); m/e- 
442.64 (M+1); Calculated- C=78.89, 
H=5.25, N=15.86; found C=78.83, H=5.27, 
N=15.84. 
6-(4-fluorophenyl)-1-(4-methylquinolin-2-
yl)-4-p-tolyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5f) 
Yield- 68 %; M.pt.- 160-162 °C; IR- 
NH2 str (3462, 3346), =C-H Str (3053), C=N 
(1602), C-F (602); 1HNMR (CDCl3) δ- 8.23 
(s, 1H, 3rd position of quinoline), 7.2-7.7 (m, 
13H, aromatic ring), 5.4 (s, 2H, NH2), 2.66 
(s, 3H, CH3 of quinoline), 2.13 (s, 3H, CH3); 
m/e- 460.34 (M+1); Calculated- C=75.80, 
H=4.83, N=15.24; Found- C=75.84, H=4.86, 
N=15.30. 
6-(4-methoxyphenyl)-1-(4-methylquinolin-2-
yl)-4-p-tolyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5g) 
Yield- 70 %; M.pt.- 163-165 °C; IR- 
NH2 str (3459, 3343), =C-H Str (3057), C=N 
(1603), C-O-C (1162); 1HNMR (CDCl3) δ- 
8.18 (s, 1H, 3rd position of quinoline), 7.1-
7.9 (m, 13H, aromatic ring), 5.7 (s, 2H, 
NH2), 3.86 (s, 3H, OCH3), 2.58 (s, 3H, CH3 
of quinoline), 2.27 (s, 3H, CH3); m/e- 472.23 
(M+1); Calculated- C=76.41. H=5.34, 
N=14.85; Found- C=76.25, H=5.47, 
N=14.88. 
1-(4-methylquinolin-2-yl)-6-(thiophen-2-yl)-
4-p-tolyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5h)  
Yield- 70 %; M.pt.- 155-157 °C; IR- 
NH2 str (3450, 3347), =C-H Str (3052), C=N 
(1607); 1HNMR (CDCl3) δ- 8.24 (s, 1H, 3rd 
position of quinoline), 7.2-7.9 (m, 12H, aro-
matic ring), 5.7 (s, 2H, NH2), 2.52 (s, 3H, 
CH3 of quinoline), 2.26 (s, 3H, CH3); m/e-
448.45 (M+1); Calculated- C=72.46, 
H=4.73, N=15.65; Found- C=72.48, H=5.42, 
N=15.63. 
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1-(4-methylquinolin-2-yl)-4,6-dip-tolyl-1H-
pyrazolo[3,4-b]pyridin-3-amine (5i) 
Yield- 70 %; M.pt.- 161-163 °C; IR- 
NH2 str (3451, 3343), =C-H Str (3050), C=N 
(1600); 1HNMR (CDCl3) δ- 8.23 (s, 1H, 3rd 
position of quinoline), 7.1-7.8 (m, 13H, aro-
matic ring), 5.2 (s, 2H, NH2), 2.52 (s, 3H, 
CH3 of quinoline), 2.21 (s, 3H, CH3), 2.26 
(s,3H, CH3); m/e-456.34 (M+1); Calculated- 
C=79.10, H=5.53, N=15.37; Found- 
C=79.15, H=5.58, N=15.40. 
4-(4-methoxyphenyl)-1-(4-methylquinolin-2-
yl)-6-phenyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5j) 
Yield- 68 %; M.pt.- 148-150 °C; IR- 
NH2 str (3450, 3342), =C-H Str (3045), C=N 
(1602), C-O-C (1155); 1HNMR (CDCl3) δ- 
8.16 (s, 1H, 3rd position of quinoline), 7.1-
7.7 (m, 14H, aromatic ring), 5.3 (s, 2H, 
NH2), 3.81 (s, 3H, OCH3), 2.62 (s, 3H, CH3 
of quinoline); m/e-458.46 (M+1); Calculat-
ed- C=76.13, H=5.07, N=15.31; found 
C=76.36, H=5.08, N=15.60. 
6-(4-fluorophenyl)-4-(4-methoxyphenyl)-1-
(4-methylquinolin-2-yl)-1H-pyrazolo[3,4-
b]pyridin-3-amine (5k) 
Yield- 70 %; M.pt.- 167-169 °C; IR- 
NH2 str (3453, 3350), =C-H Str (3043), C=N 
(1610), C-O-C (1170), C-F (600); 1HNMR 
(CDCl3) δ- 8.16 (s, 1H, 3rd position of quino-
line), 7.1-7.7 (m, 13H, aromatic ring), 5.3 (s, 
2H, NH2), 3.81 (s, 3H, OCH3), 2.62 (s, 3H, 
CH3 of quinoline); m/e-476.64 (M+1); Cal-
culated- C=73.25, H=4.66, N=14.73; Found- 
73.56, H=4.65, N=14.86. 
4,6-bis(4-methoxyphenyl)-1-(4-
methylquinolin-2-yl)-1H-pyrazolo[3,4-
b]pyridin-3-amine (5l) 
Yield- 70 %; M.pt.- 170-172 °C; IR- 
NH2 str (3455, 3346), =C-H Str (3055), C=N 
(1605), C-O-C (1165); 1HNMR (CDCl3) δ- 
8.25 (s, 1H, 3rd position of quinoline), 7.2-
7.8 (m, 13H, aromatic ring), 5.8 (s, 2H, 
NH2), 3.83 (s, 3H, OCH3), 3.87 (s, 3H, 
OCH3), 2.54 (s, 3H, CH3 of quinoline); m/e- 
488.53 (M+1); Calculated- C=73.90. 
H=5.17, N=14.36; Found- C=73.85, H=5.37, 
N=14.24. 
4-(4-methoxyphenyl)-1-(4-methylquinolin-2-
yl)-6-(thiophen-2-yl)-1H-pyrazolo[3,4-
b]pyridin-3-amine (5m) 
Yield- 62 %; M.pt.- 169-171 °C; IR- 
NH2 str (3451, 3344), =C-H Str (3051), C=N 
(1600); 1HNMR (CDCl3) δ- 8.28 (s, 1H, 3rd 
position of quinoline), 7.1-7.7 (m, 12H, aro-
matic ring), 5.6 (s, 2H, NH2), 3.83 (s, 3H, 
OCH3), 2.51 (s, 3H, CH3 of quinoline); m/e- 
464.18 (M+1); Calculated- C=69.96, 
H=4.57, N=15.11; Found- C=69.86, H=4.64, 
N=15.18. 
4-(4-methoxyphenyl)-1-(4-methylquinolin-2-
yl)-6-p-tolyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5n) 
Yield- 65 %; M.pt.- 160-162 °C; IR- 
NH2 str (3446, 3325), =C-H Str (3055), C=N 
(1600), C-O-C (1165); 1HNMR (CDCl3) δ- 
8.46 (s, 1H, 3rd position of quinoline), 7.2-
7.8 (m, 13H, aromatic ring), 5.5 (s, 2H, 
NH2), 3.80 (s, 3H, OCH3), 2.53 (s, 3H, CH3 
of quinoline), 2.19 (s, 3H, CH3); m/e- 472.54 
(M+1); Calculated- C=76.41. H=5.34, 
N=14.85; Found- C=76.44, H=5.40, 
N=14.86. 
4-(4-chlorophenyl)-1-(4-methylquinolin-2-
yl)-6-phenyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5o) 
Yield- 68 %; M.pt.- 152-154 °C; IR- 
NH2 str (3450, 3348), =C-H Str (3055), C=N 
(1604), C-Cl (658); 1HNMR (CDCl3) δ- 8.13 
(s, 1H, 3rd position of quinoline), 7.2-7.5 (m, 
14H, aromatic ring), 5.9 (s, 2H, NH2), 2.62 
(s, 3H, CH3 of quinoline); m/e- 462.96 
(M+1); Calculated- C=72.80, H=4.36, 
N=15.16; found C=72.76, H=4.28, N=15.10. 
4-(4-chlorophenyl)-6-(4-fluorophenyl)-1-(4-
methylquinolin-2-yl)-1H-pyrazolo[3,4-
b]pyridin-3-amine (5p) 
Yield- 67 %; M.pt.- 160-163 °C; IR- 
NH2 str (3451, 3350), =C-H Str (3051), C=N 
(1603), C-Cl (656), C-F (602); 1HNMR 
(CDCl3) δ- 8.26 (s, 1H, 3rd position of quino-
line), 7.3-7.9 (m, 13H, aromatic ring), 5.2 (s, 
2H, NH2), 2.59 (s, 3H, CH3 of quinoline); 
m/e- 480.96 (M+1); Calculated- C=70.07, 
H=3.99, N=14.59; found C=70.12, H=3.95, 
N=14.54. 
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4-(4-chlorophenyl)-6-(4-methoxyphenyl)-1-
(4-methylquinolin-2-yl)-1H-pyrazolo[3,4-
b]pyridin-3-amine (5q) 
Yield- 67 %; M.pt.- 160-163 °C; IR- NH2 str 
(3451, 3350), =C-H Str (3051), C=N (1603), 
C-Cl (660); 
1HNMR (CDCl3) δ- 8.15 (s, 1H, 3rd posi-
tion of quinoline), 7.2-7.9 (m, 13H, aromatic 
ring), 5.1 (s, 2H, NH2), 3.82 (s, 3H, OCH3), 
2.54 (s, 3H, CH3 of quinoline); m/e- 492.56 
(M+1); Calculated- C=70.80, H=4.51, 
N=14.24; found C=70.69, H=3.94, N=14.54. 
4-(4-chlorophenyl)-1-(4-methylquinolin-2-
yl)-6-p-tolyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5r) 
Yield- 69 %; M.pt.- 164-166 °C; IR- 
NH2 str (3458, 3354), =C-H Str (3053), C=N 
(1608), C-Cl (661); 
1HNMR (CDCl3) δ- 8.23 (s, 1H, 3rd posi-
tion of quinoline), 7.3-7.9 (m, 13H, aromatic 
ring), 5.5 (s, 2H, NH2), 2.54 (s, 3H, CH3 of 
quinoline, 2.14 (s, 3H, CH3); m/e- 476.44 
(M+1); Calculated- C=73.18. H=4.66, 
N=14.71; Found- C=73.42, H=4.68, 
N=14.80. 
4-(4-fluorophenyl)-1-(4-methylquinolin-2-
yl)-6-phenyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5s) 
Yield- 64 %; M.pt.- 156-159 °C; IR- 
NH2 str (3451, 3346), =C-H Str (3051), C=N 
(1600), C-F (604); 1HNMR (CDCl3) δ- 8.20 
(s, 1H, 3rd position of quinoline), 7.1-7.7 (m, 
14H, aromatic ring), 5.2 (s, 2H, NH2), 2.61 
(s, 3H, CH3 of quinoline); m/e- 446.46 
(M+1); Calculated- C=75.49, H=4.54, 
N=15.72; found C=75.46, H=4.51, N=15.70. 
4-(4-fluorophenyl)-1-(4-methylquinolin-2-
yl)-6-p-tolyl-1H-pyrazolo[3,4-b]pyridin-3-
amine (5t) 
Yield- 66 %; M.pt.- 162-164 °C; IR- 
NH2 str (3461, 3338), =C-H Str (3055), C=N 
(1601), C-F (604); 1HNMR (CDCl3) δ- 8.21 
(s, 1H, 3rd position of quinoline), 7.1-7.7 (m, 
13H, aromatic ring), 5.6 (s, 2H, NH2), 2.61 
(s, 3H, CH3 of quinoline), 2.12 (s, 3H, CH3); 
m/e- 460.54 (M+1);Calculated- C=75.80, 
H=4.83, N=15.24; Found- C=75.82, H=4.81, 
N=15.28. 
In vitro antimalarial activity 
The schizont maturation assay was used 
to evaluate the in vitro activity of synthe-
sized series (Pandey et al., 2016). In schi-
zontocidal assay of test samples, parasitized 
blood was made by infecting red blood cells 
with CQ-S (3D7) strain of P. falciparum 
with 2-3 % parasitemia in RPMI 1640 medi-
um. The parasite cultures, prior to experi-
mentation, were synchronized by treatment 
with 5 % D-sorbitol. Stock solutions of sam-
ples were prepared separately for all the syn-
thetic derivatives, diluting with DMSO to a 
concentration of 1 mg/ml. Serial double dilu-
tions of each set of test compounds were 
made in 96 well microtiter plates with con-
centration ranging from 1.8–500 μg/ml 
against a control containing the incomplete 
medium with same concentration of DMSO. 
In each well 100 μl of the diluted test com-
pound, 10 μl parasitized blood (4 – 5 % 
rings) in 100 μl incomplete medium. Four 
wells of the last row were set as general con-
trols to check the normal growth of the para-
site. The plates were incubated at 37 °C in 
gas mixture of 90 % N2, 5 % CO2 and 5 % 
O2 for 24 h. A thick blood smear was pre-
pared from all wells and stained with giemsa 
stain. Numbers of schizonts were counted 
per 200 asexual stage parasites. The values 
were compared between test and control 
wells. 
 
In vivo antimalarial activity 
Acute toxicity testing was performed as 
per OECD-423 (Ecobichon, 1977). The ani-
mals were checked for any abnormal behav-
ior for 30 minutes and then after every 4 h. 
After calculating LD50, the in vivo antimalar-
ial efficacy was determined by Peter's 4 day 
suppressive test (Peters et al., 1975). Malaria 
infection was established in mice by inocula-
tation on the first day (day 0), intraperitone-
ally, with 0.2 ml of infected blood containing 
about 1×107 P. berghei parasitized erythro-
cytes. The animals were divided into groups 
of five mice each and orally administered, 
shortly after inoculation, with 200 mg/kg 
doses of test compounds for 4 consecutive 
EXCLI Journal 2016;15:730-737 – ISSN 1611-2156 
Received: October 03, 2016, accepted: November 02, 2016, published: November 28, 2016 
 
 
735 
days. Chloroquine (5mg/kg body weight) 
was administered positive (standard) control 
group and negative control group were ad-
ministered the same amount of solvent used 
to suspend the test compound. On the fourth 
day, blood was withdrawn from tail vein of 
mice. Thin smears were made, fixed with 
methanol and stained with Giemsa. Para-
sitemia was examined microscopically and 
percent suppression was subsequently calcu-
lated.  
 
RESULTS AND DISCUSSION 
Chemistry 
Substituted acetophenones underwent 
cyano condensation reaction with different 
aromatic aldehyde, ethyl cyanoacetate and 
excess of ammonium acetate in n-butanol to 
give corresponding 3(a-t). IR spectrum of 
compounds confirmed the synthetic product 
by exhibiting absorption band at 3439 due to 
NH group, 2223 due to CN and 1640 due to 
C=O group. 1H NMR also showed singlet 
signal at 12.1 due to NH protons. Further 
heating compounds 3(a-t) with phosphorous 
oxychloride and phosphorous pentachloride 
led to the synthesis of 2-chloro pyridines 
4(a-t) which upon further reaction with 2-
hydrazino-4-methyl-quinoline afforded pyra-
zolo pyridine derivatives 5(a-t). The struc-
ture of target compounds were confirmed by 
their elemental analysis and spectral data.IR 
spectrum displayed band at 3454 and 3342 
for NH2 and band for C=N at 1601 cm-1. One 
more characteristic band C=N near 2200 cm-
1 disappeared. 
 
Biological activity 
In vitro antimalarial activity 
All the synthesized 20 compounds were 
screened in vitro for their anti-malarial po-
tential using schizont maturation inhibition. 
EC50 values for all the compounds are enlist-
ed in Table 1. The activities of compounds 
appeared in the following order: 
5p > 5k > 5q > 5b > 5s > 5o > 5l > 5j > 5c 
> 5a > 5m > 5t > 5r > 5f > 5d > 5n > 5g > 5e 
> 5h > 5i. 
The results revealed that the compounds 
with halogen were having moderate to good 
activity. Among the series, compound 5p, 
which was substituted with chalcone and 
fluorine at para position of two phenyl rings, 
was found to be the best. Similarly com-
pounds 5b, 5k, 5o, 5q and 5s displayed good 
anti-malarial activity with EC50 1.921-2.916 
µg/ml. All these compounds were substituted 
with halogen on at least one phenyl ring. Re-
sults also revealed that the presence of –CH3 
group led to the reduction in anti-malarial 
potential. Compound 5i was found to be the 
least effective with EC50 10.929 µg/ml. 
Compounds 5b, 5k, 5p, 5q, and 5s were fur-
ther screened for their in vivo anti-malarial 
potential. 
 
In vivo antimalarial activity 
Dose was calculated by acute toxicity 
studies. All the compounds were found to 
possess dosage of 200 mg/kg. Further com-
pounds were tested in vivo for anti-malarial 
activity by 4 day suppression. Result for 
each compound has been displayed in table 
2. Compound 5p was found to be the most 
effective with %age suppression of 60.25 % 
while standard treatment cured all the five 
animals with 100 % suppression and 100 % 
survival rate. On 7th day, 4 out of 5 mice re-
mained alive using treatment with the test 
compound 5p. The order of activity was ob-
served as 5p > 5k > 5q > 5b > 5s. 
The results divulged that presence of 
halogens on both the rings led to highest 
suppression of parasitemia. 
 
CONCLUSION 
In the present research work, we have 
synthesized different derivatives of cyano-
pyridines which were effectively converted 
into quinoline based pyrazolopyridine deriv-
atives. Most of the compounds displayed 
significant potential for anti-malarial activi-
ty. Compound 5p exhibited best in vitro as 
well as in vivo anti-malarial activity among 
the series and was comparable with the 
standard chloroquine. These results indicate 
that the pyrazolopyridine-quinoline hybrids 
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may be promising leads and may also be 
proved as significant model for further struc-
tural as well as biological optimization. 
 
 
 
 
Table 1: In Vitro antimalarial activity of synthetic derivatives 5(a-t) against CQ-Sensitive 3d7 strain of 
P. falciparum 
Sr. no. Compounds Ar’ Ar EC50(µg/ml) 
1 5a C6H5- C6H5- 2.934 
2 5b C6H5- 4-F C6H4- 2.081 
3 5c C6H5- 4-OCH3 C6H4- 2.721 
4 5d C6H5- 
S
6.312 
5 5e 4-CH3 C6H4- C6H5- 8.012 
6 5f 4-CH3 C6H4- 4-F C6H4- 5.412 
7 5g 4-CH3 C6H4- 4-OCH3 C6H4- 7.211 
8 5h 4-CH3 C6H4- 
S
9.497 
9 5i 4-CH3 C6H4- 4-CH3 C6H4- 10.929 
10 5j 4-OCH3 C6H4- C6H5- 2.593 
11 5k 4-OCH3 C6H4- 4-F C6H4- 1.921 
12 5l 4-OCH3 C6H4- 4-OCH3 C6H4- 2.321 
13 5m 4-OCH3 C6H4-
S
3.562 
14 5n 4-OCH3 C6H4- 4-CH3 C6H4- 7.101 
15 5o 4-Cl C6H4- C6H5- 2.196 
16 5p 4-Cl C6H4- 4-F C6H4- 1.734 
17 5q 4-Cl C6H4- 4-OCH3 C6H4- 1.983 
18 5r 4-Cl C6H4- 4-CH3 C6H4- 5.345 
19 5s 4-F C6H4- C6H5- 2.191 
20 5t 4-F C6H4- 4-CH3 C6H4- 4.962 
 
 
Table 2: In vivo antimalarial activity of 5 selected compounds against P. berghei strain in Swiss albino 
mice 
S.No. Drug  treatment Dose/kg 
No. of 
animals % parasitemia
Percentage 
inhibition 
Survival  
on 7th day 
1. Control - 5 49.62 ± 0.304 - 0/5 
2. Standard 5 mg/kg 5 - 100 5/5 
3. 5b 200 mg/kg1 5 34.12 ± 0.103 31.24** 3/5 
4. 5k 200 mg/kg1 5 29.01 ± 0.112 41.54** 4/5 
5. 5p 200 mg/kg1 5 19.72 ± 0.121 60.25** 5/5 
6. 5q 200 mg/kg1 5 32.73 ± 0.231 34.04** 3/5 
7. 5s 200 mg/kg1 5 36.27 ± 0.142 26.90** 1/5 
1:- dose calculated by acute toxicity method; N=5, Values are expressed as Mean ± SEM and analyzed 
by ANOVA. **P < 0.01(significant). Values are compared with control group. 
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